Priya Singhal - Feb 17, 2023 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role: Head of Development
Signature: /s/ Wendell Taylor, attorney-in-fact for Priya Singhal
Stock symbol: BIIB
Transactions as of: Feb 17, 2023
Transactions value $: -$42,035
Form type: 4
Date filed: 2/22/2023, 04:07 PM
Previous filing: Feb 14, 2023
Next filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BIIB	Common Stock	Options Exercise	$0	+460	+13.18%	$0.00	3.95K	Feb 17, 2023	Direct
transaction	BIIB	Common Stock	Tax liability	-$42K	-151	-3.82%	$278.38	3.8K	Feb 17, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BIIB	Restricted Stock Unit	Options Exercise	$0	-460	-26.41%	$0.00	1.28K	Feb 17, 2023	Common Stock	460	$0.00	Direct	F1
transaction	BIIB	Restricted Stock Unit	Other	$0	-408	-31.83%	$0.00	874	Feb 17, 2023	Common Stock	408	$0.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2	This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

Content

This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.